Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Therapeutic Solutions’ Res Nova Bio Reports Positive Data in Advanced Cancer
Details : FloraStilbene (mifepristone and pterostilbene) aims to stimulate the immune system in advanced breast cancer patients, with preclinical data showing efficacy in a triple-negative breast cancer model.
Brand Name : FloraStilbene
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 03, 2024
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Res Nova Biologics Announces First Cancer Patient Treated with FloraStilbene™
Details : FloraStilbene (RU486 and pterostilbene) to stimulate the immune system in advanced breast cancer patients. Preclinical data demonstrated that FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
Brand Name : FloraStilbene
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 20, 2023
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cure Stat Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Cure Stat Rx will manufacture first in class breast cancer immunotherapy product FloraStilbene™ for a planned 12 patient Phase I/II trial aimed at assessing immunomodulatory activity of the drug candidate in advanced breast can...
Brand Name : FloraStilbene
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : Mifepristone,Pterostilbene
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cure Stat Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JadiCells, as well as QuadraMune®, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.
Brand Name : QuadraMune
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 22, 2021
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
QuadraMune™ Synergizes with Metformin to Stimulate Anti-Viral Defenses in Pilot Clinical Trial
Details : Using a standard test for natural killer cell activity, the K562 lysis assay, 12 healthy volunteers taking one week of placebo had an average activity of 2.3 (±0.6), whereas those taking one week of QuadraMune™ had an average activity of 5.2 (±1.2), ...
Brand Name : QuadraMune
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 24, 2020
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.
Brand Name : QuadraMune
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 28, 2020
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Pterostilbene is one of four ingredients which comprise QuadraMune™, a nutraceutical being developed by the Company which is currently in a clinical trial for prevention of COVID-19.
Brand Name : QuadraMune
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 28, 2020
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company showed that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a “cancer vaccine.
Brand Name : QuadraMune
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 11, 2020
Lead Product(s) : Pterostilbene,Green Tea Extract,Sulforaphane
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pterostilbene,Sulforaphane,Green Tea Extract
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Administration of daily doses of QuadraMune™ in healthy volunteers results in statistically significant increases in immune response activity within 5 days.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : Pterostilbene,Sulforaphane,Green Tea Extract
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?